BRPI9917760B8 - método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada - Google Patents

método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada

Info

Publication number
BRPI9917760B8
BRPI9917760B8 BRPI9917760A BR9917760A BRPI9917760B8 BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8 BR PI9917760 A BRPI9917760 A BR PI9917760A BR 9917760 A BR9917760 A BR 9917760A BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8
Authority
BR
Brazil
Prior art keywords
uricase
isolating
purified
solution
tetrameric form
Prior art date
Application number
BRPI9917760A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9917760B1 (pt
Inventor
L Williams David
G P Saifer Mark
R Sherman Merry
S Hershfield Michael
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR9917760B1 publication Critical patent/BR9917760B1/pt
Publication of BRPI9917760B8 publication Critical patent/BRPI9917760B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI9917760A 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada BRPI9917760B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13039298A 1998-08-06 1998-08-06
US09/130,132 1998-08-06
PCT/US1999/017514 WO2000007629A2 (en) 1998-08-06 1999-08-02 Peg-urate oxidase conjugates and use thereof

Publications (2)

Publication Number Publication Date
BR9917760B1 BR9917760B1 (pt) 2014-11-25
BRPI9917760B8 true BRPI9917760B8 (pt) 2021-05-25

Family

ID=22444494

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9917760A BRPI9917760B8 (pt) 1998-08-06 1999-08-02 método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9912974A BRPI9912974B8 (pt) 1998-08-06 1999-08-02 conjugados de peg-urato oxidase e seu uso

Country Status (13)

Country Link
EP (1) EP1100542B1 (OSRAM)
JP (3) JP5183836B2 (OSRAM)
KR (2) KR100488848B1 (OSRAM)
AU (1) AU770014B2 (OSRAM)
BR (2) BRPI9917760B8 (OSRAM)
CZ (1) CZ303751B6 (OSRAM)
HU (2) HU228916B1 (OSRAM)
IL (3) IL141220A0 (OSRAM)
NZ (1) NZ509595A (OSRAM)
PL (2) PL202799B1 (OSRAM)
RU (3) RU2246318C2 (OSRAM)
TW (1) TW570981B (OSRAM)
WO (1) WO2000007629A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183836B2 (ja) * 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
DE69943205D1 (de) 1998-08-06 2011-03-31 Mountain View Pharmaceuticals Peg-uricase Konjugate und Verwendung davon
ES2352451T3 (es) 1998-08-06 2011-02-18 Duke University Urato oxidasa.
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU2006203252B8 (en) * 2000-02-10 2009-06-18 Duke University Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CN100479862C (zh) 2000-04-03 2009-04-22 参天制药株式会社 释放物质和采用该物质的药物释放系统
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
AU2002345938A1 (en) 2001-06-28 2003-03-03 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2004238868B2 (en) 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CA2525399A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
SI3321359T1 (sl) 2005-04-11 2021-07-30 Horizon Pharma Rheumatology Llc Variantne oblike urat oksidaze in uporaba le-teh
EP1871877A2 (en) * 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CN101622270B (zh) * 2006-04-12 2014-01-01 萨文特医药公司 用阳离子表面活性剂纯化蛋白质的方法
JP4890132B2 (ja) * 2006-07-20 2012-03-07 東洋紡績株式会社 ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ
RU2382048C1 (ru) * 2008-12-25 2010-02-20 Общество С Ограниченной Ответственностью "Фармапарк" Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием
CN102803954A (zh) 2009-06-25 2012-11-28 萨文特制药公司 通过监测peg化尿酸酶治疗期间的血清尿酸预测输液反应风险和抗体介导的响应丧失的方法和试剂盒
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
US9744175B2 (en) 2012-04-06 2017-08-29 Indus Pharmaceuticals, Inc. Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
KR20240119155A (ko) 2013-05-03 2024-08-06 셀렉타 바이오사이언시즈, 인크. 감소 또는 증진된 약역학적 효과를 위한 관용유발 합성 나노담체 및 치료 거대분자
WO2016187026A1 (en) * 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
HUE072005T2 (hu) 2017-03-11 2025-10-28 Cartesian Therapeutics Inc Gyulladásgátlókkal és immunszupresszánst tartalmazó szintetikus nanohordozókkal történõ kombinált kezeléssel összefüggõ eljárások és készítmények
CN112980808B (zh) * 2019-12-12 2024-10-29 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN114438047B (zh) * 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
EP4293117A4 (en) 2021-02-10 2025-03-26 Oriental Yeast Co., Ltd. Urine activator and uric acid measuring reagent
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1529675A (fr) * 1967-03-29 1968-06-21 Applic Biochimiques Soc Et Urate oxydase à haute activité et sa préparation
US3616231A (en) * 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6031472B2 (ja) * 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
JPS55135590A (en) * 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
JPS57192435A (en) * 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2352451T3 (es) * 1998-08-06 2011-02-18 Duke University Urato oxidasa.
JP5183836B2 (ja) * 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用

Also Published As

Publication number Publication date
BRPI9912974B8 (pt) 2021-05-25
RU2246318C2 (ru) 2005-02-20
HU228916B1 (en) 2013-06-28
EP1100542A2 (en) 2001-05-23
WO2000007629A2 (en) 2000-02-17
RU2006107111A (ru) 2007-09-20
RU2349341C2 (ru) 2009-03-20
AU5251599A (en) 2000-02-28
JP2009254376A (ja) 2009-11-05
JP2002522399A (ja) 2002-07-23
HUP0103003A2 (hu) 2001-11-28
CZ303751B6 (cs) 2013-04-24
IL183948A (en) 2010-11-30
IL141220A (en) 2007-09-20
HU226294B1 (en) 2008-08-28
BR9917760B1 (pt) 2014-11-25
TW570981B (en) 2004-01-11
CZ2001317A3 (cs) 2001-07-11
BRPI9912974B1 (pt) 2015-08-25
KR100488848B1 (ko) 2005-05-11
JP5290901B2 (ja) 2013-09-18
JP5183836B2 (ja) 2013-04-17
EP1100542B1 (en) 2005-06-22
KR20010072287A (ko) 2001-07-31
RU2278680C2 (ru) 2006-06-27
PL346224A1 (en) 2002-01-28
PL202799B1 (pl) 2009-07-31
AU770014B2 (en) 2004-02-12
IL141220A0 (en) 2002-03-10
IL183948A0 (en) 2007-10-31
BR9912974A (pt) 2001-05-08
KR20040088585A (ko) 2004-10-16
RU2004104953A (ru) 2005-07-27
NZ509595A (en) 2004-02-27
JP2013039139A (ja) 2013-02-28
PL220873B1 (pl) 2016-01-29
WO2000007629A3 (en) 2000-06-08
JP5291235B2 (ja) 2013-09-18
PL383331A1 (OSRAM) 2002-01-28
HUP0103003A3 (en) 2006-04-28
KR100614212B1 (ko) 2006-08-21

Similar Documents

Publication Publication Date Title
BRPI9917760B8 (pt) método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
AU5624699A (en) Use of 5ht-6 antagonists
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
MXPA05011223A (es) Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
IL183953A (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor
BR9910251A (pt) Estimulação hematopoiética
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
BR0211442A (pt) Cepas de bifidobacterium probióticas
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
DE69943205D1 (de) Peg-uricase Konjugate und Verwendung davon
SG161247A1 (en) Variant forms of urate oxidase and use thereof
BR0311161A (pt) Método de tratamento de diabetes
HK1047707A1 (zh) (+)-曲马朵、o-去甲曲马朵或(+)-o-去甲曲马朵、o-去甲-n-单-去甲-曲马朵或(+)-o-去甲-n-单-去甲-曲马朵治疗尿失禁的用途
WO2002018361A3 (en) Compounds having activity as inhibitors of cytochrome p450rai
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2002074344A3 (en) Peg-conjugates of hgt-nk4
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2005056040A3 (en) Systems and methods related to degradation of uremic toxins
WO2002064816A3 (en) Multiple determinants for metabolic phenotypes
WO2004069781A3 (en) 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity
WO2001007644A3 (en) Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
NO20051390L (no) Fremgangsmate for behandling av pasienter med massivt blodtap
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)

Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B24E Patent annual fee: resolution cancelled

Free format text: REFERENTE AO DESPACHO 24.8 PUBLICADO NA RPI 2289 DE 18/11/2014.

B15K Others concerning applications: alteration of classification

Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.0

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/08/2019